News
News
Advertisement
Teresa Hagan Thomas, PhD, RNNews | September 21, 2023
The model uses patient-generated data to triage surgical oncology patients with the goal of improving post-surgical outcomes.
Read More
Patrick DalyConferences | September 15, 2023
Patients with ibrutinib dose reductions after AEs had longer treatments and similar outcomes to those without reductions.
Patrick DalyConferences | September 15, 2023
Patients with CLL who relapsed after HSCT and then received venetoclax achieved outcomes consistent with trial data.
Patrick DalyConferences | September 15, 2023
The rituximab, fludarabine, and cyclophosphamide regimen appeared to be most effective for overall survival and response.
Patrick DalyConferences | September 15, 2023
Data suggest patients with CLL are more anxious when receiving intravenous versus oral treatment.
Dustin SamplesConferences | September 13, 2023
It is important to monitor patients who have elevated CMV levels to detect infection and progression early.
Dustin SamplesConferences | September 13, 2023
Results from this meta-review suggest that more prophylactic strategies are needed in the fight against GVHD.
Dustin SamplesConferences | September 13, 2023
Intensive salvage therapy had a 54% complete remission rate whereas non-intensive salvage therapy was lower at 18%.
Milagros Elia, MA, APRN, ANP-BCVideos | September 12, 2023
Milagros Elia, MA, APRN, ANP-BC, discusses the tragic fires in Maui and the massive impact these events have on cancer care.
Dustin SamplesConferences | September 8, 2023
The study used only single-agent tacrolimus for GVHD prophylaxis.
Dustin SamplesConferences | September 8, 2023
Non-relapse mortality was low, and there was good GVHD control with the prophylaxis.
Dustin SamplesConferences | September 8, 2023
Results were further improved when Orca-T was given in combination with a regimen of busulfan, fludarabine, and thiotepa.
Cailin ConnerConferences | September 8, 2023
Limited diagnostic resources, such as EPO level tests, can result in late or misdiagnosis and increased health care costs.
Cailin ConnerConferences | September 8, 2023
The average cost of hospitalization for a TE was $4000-9000 higher than for generally medically ill patients.
Cailin ConnerConferences | September 8, 2023
Investigators noted improved spleen size and blood parameters in addition to improvement in PV symptoms.
Dustin SamplesConferences | September 8, 2023
Rusfertide improved response maintenance and reduced the need for therapeutic phlebotomy.
Dustin SamplesGVHD | September 7, 2023
The trial cohort achieved a staggering 100% overall response rate after 7 days of treatment.
Dustin SamplesGVHD | September 7, 2023
The improvements occurred after haploidentical donor-matched transplant with PTCy and cord blood transplant.
Dustin SamplesConferences | September 6, 2023
Findings from this pilot study suggest that EVs may be a promising avenue for developing ocular GvHD therapies.
Dustin SamplesConferences | September 6, 2023
Differences in microRNA expression could help identify individuals at risk of developing GVHD.
Advertisement
Advertisement
Advertisement